Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.
Nagahashi M, Ishikawa E, Nagai T, Kanaoka H, Oshiro A, Togashi Y, Hattori A, Tsuchida J, Higuchi T, Nishimukai A, Murase K, Takatsuka Y, Kihara T, Ling Y, Okuda S, Hirota S, Miyoshi Y. Nagahashi M, et al. Among authors: nishimukai a. Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01665-y. Online ahead of print. Breast Cancer. 2025. PMID: 39808396
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer.
Mitsuyoshi A, Nagahashi M, Kanaoka H, Oshiro A, Togashi Y, Hattori A, Tsuchida J, Higuchi T, Nishimukai A, Murase K, Takatsuka Y, Miyoshi Y. Mitsuyoshi A, et al. Among authors: nishimukai a. Int J Clin Oncol. 2024 Dec;29(12):1850-1859. doi: 10.1007/s10147-024-02625-w. Epub 2024 Sep 15. Int J Clin Oncol. 2024. PMID: 39278979
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.
Miyagawa Y, Yanai A, Yanagawa T, Inatome J, Egawa C, Nishimukai A, Takamoto K, Morimoto T, Kikawa Y, Suwa H, Taji T, Yamaguchi A, Okada Y, Sata A, Fukui R, Bun A, Ozawa H, Higuchi T, Fujimoto Y, Imamura M, Miyoshi Y. Miyagawa Y, et al. Among authors: nishimukai a. Oncotarget. 2020 Jan 7;11(1):86-98. doi: 10.18632/oncotarget.27423. eCollection 2020 Jan 7. Oncotarget. 2020. PMID: 32002126 Free PMC article.
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, Nishimukai A, Kira A, Imamura M, Takatsuka Y, Miyoshi Y. Miyagawa Y, et al. Among authors: nishimukai a. Clin Breast Cancer. 2018 Oct;18(5):400-409. doi: 10.1016/j.clbc.2018.03.002. Epub 2018 Mar 8. Clin Breast Cancer. 2018. PMID: 29605174 Free article.
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M, Morimoto T, Nomura T, Michishita S, Nishimukai A, Higuchi T, Fujimoto Y, Miyagawa Y, Kira A, Murase K, Araki K, Takatsuka Y, Oh K, Masai Y, Akazawa K, Miyoshi Y. Imamura M, et al. Among authors: nishimukai a. World J Surg Oncol. 2018 Feb 12;16(1):26. doi: 10.1186/s12957-018-1325-6. World J Surg Oncol. 2018. PMID: 29433529 Free PMC article.
Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
Nishimukai A, Inoue N, Kira A, Takeda M, Morimoto K, Araki K, Kitajima K, Watanabe T, Hirota S, Katagiri T, Nakamori S, Akazawa K, Miyoshi Y. Nishimukai A, et al. PLoS One. 2017 Sep 8;12(9):e0184508. doi: 10.1371/journal.pone.0184508. eCollection 2017. PLoS One. 2017. PMID: 28886153 Free PMC article.
High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
Imamura M, Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Sakita I, Hatada T, Takatsuka Y, Katagiri T, Miyoshi Y. Imamura M, et al. Among authors: nishimukai a. Breast Cancer Res Treat. 2015 Dec;154(3):521-31. doi: 10.1007/s10549-015-3638-2. Epub 2015 Nov 16. Breast Cancer Res Treat. 2015. PMID: 26573829
16 results